These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 25739820)

  • 1. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.
    Lonardo A; Ballestri S; Marchesini G; Angulo P; Loria P
    Dig Liver Dis; 2015 Mar; 47(3):181-90. PubMed ID: 25739820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, Risk Profiles, and National Implications of Nonalcoholic Fatty Liver Disease in Pregnant Individuals.
    Kushner T; Lange M; Argiriadi PA; Meislin R; Sigel K; Terrault N;
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):194-196.e1. PubMed ID: 37031718
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease: Erratum.
    Hepatol Commun; 2023 Feb; 7(2):e0077. PubMed ID: 38345897
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitamin A in Nonalcoholic Fatty Liver Disease: A Key Player in an Offside Position?
    Berasain C; Avila MA
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):291-293. PubMed ID: 32971038
    [No Abstract]   [Full Text] [Related]  

  • 5. Helicobacter pylori and metabolic syndrome-related adipokines in nonalcoholic fatty liver disease pathophysiology.
    Kountouras J; Zavos C; Vardaka E; Kyrailidi F; Mouratidou MC; Tzitiridou-Chatzopoulou M; Orovou E; Touloumtzi M; Papanikolaou IS; Kazakos E
    J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38725326
    [No Abstract]   [Full Text] [Related]  

  • 6. Using race as a social construct when looking at differences in racial associations between non‑alcoholic fatty liver disease and type 2 diabetes. Reply to Rollin FG, Washington C, Fluker S-A [letter].
    Hatano Y; VanWagner LB; Carnethon MR; Bancks MP; Carson AP; Lloyd-Jones DM; Østbye T; Viera AJ; Yano Y
    Diabetologia; 2024 Jan; 67(1):213-214. PubMed ID: 37882861
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological, Endoscopic, Metabolic, and Surgical Procedures for Nonalcoholic Fatty Liver Disease.
    Xanthakos SA
    Clin Liver Dis (Hoboken); 2021 Mar; 17(3):209-214. PubMed ID: 33868667
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes, nonalcoholic fatty liver disease and obesity: What is the link?
    Pustake MV; Giri P; Ganiyani MAMT; Jain S
    J Family Med Prim Care; 2024 Mar; 13(3):1119-1120. PubMed ID: 38736789
    [No Abstract]   [Full Text] [Related]  

  • 9. Imaging methods in the assessment of nonalcoholic fatty liver disease.
    Parente DB
    Radiol Bras; 2020; 53(2):IX-X. PubMed ID: 32336832
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diagnosis and treatment strategy of pediatric nonalcoholic fatty liver disease].
    Zhou XL; Fu JF
    Zhonghua Er Ke Za Zhi; 2024 Jun; 62(6):590-592. PubMed ID: 38763887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RETRACTION: Leukocyte cell-derived chemotaxin 2 affects nonalcoholic fatty liver disease.
    Wang Y; Wu A; Xi L; Yang J; Zhou W; Wang Y; Liang S; Yu W; Wang Y; Zhu J
    J Endocrinol; 2020 Sep; 246(3):Z1. PubMed ID: 32485675
    [No Abstract]   [Full Text] [Related]  

  • 12. NAFLD: a multisystem disease.
    Byrne CD; Targher G
    J Hepatol; 2015 Apr; 62(1 Suppl):S47-64. PubMed ID: 25920090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T
    FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide and mitochondria in metabolic syndrome.
    Litvinova L; Atochin DN; Fattakhov N; Vasilenko M; Zatolokin P; Kirienkova E
    Front Physiol; 2015; 6():20. PubMed ID: 25741283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of diet on non-alcoholic fatty liver disease: An updated narrative review.
    Papandreou D; Andreou E
    World J Hepatol; 2015 Mar; 7(3):575-82. PubMed ID: 25848481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?
    Ahmed MH; Husain NE; Almobarak AO
    J Family Med Prim Care; 2015; 4(1):45-52. PubMed ID: 25810989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome, aging and involvement of oxidative stress.
    Bonomini F; Rodella LF; Rezzani R
    Aging Dis; 2015 Mar; 6(2):109-20. PubMed ID: 25821639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
    Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
    Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.
    Tangvarasittichai S
    World J Diabetes; 2015 Apr; 6(3):456-80. PubMed ID: 25897356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.